Efficacy and Safety of CD28- or 4-1BB-Based CD19 CAR-T Cells in B Cell Acute Lymphoblastic Leukemia

CD19-directed chimeric antigen receptor-T (CAR-T) cells with a 4-1BB or CD28 co-stimulatory domain have shown impressive antitumor activity against relapsed or refractory B cell acute lymphoblastic leukemia (r/r B-ALL). However, a parallel comparison of their performances in r/r B-ALL therapy has no...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Mol Ther Oncolytics
Auteurs principaux: Zhao, Xiangyu, Yang, Junfang, Zhang, Xian, Lu, Xin-An, Xiong, Min, Zhang, Jianping, Zhou, Xiaosu, Qi, Feifei, He, Ting, Ding, Yanping, Hu, Xuelian, De Smet, Floris, Lu, Peihua, Huang, Xiaojun
Format: Artigo
Langue:Inglês
Publié: American Society of Gene & Cell Therapy 2020
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7378699/
https://ncbi.nlm.nih.gov/pubmed/32728615
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.omto.2020.06.016
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires